The world's leading automated proofreading software

The EMA and TVT

Published By: Marc Chaillou

2 minutes read
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Table of Contents

This may come as a surprise to regulatory affairs professionals of the pharmaceutical industry, but the European Medicines Agency (EMA) has been using TVT, the Text Verification Tool® since 2004!

Why is this relevant for Regulatory Professionals and Labelling and Graphic Designers working in Pharma?
The EMA spends a lot of time comparing texts

And in simple words, that’s what TVT does. The proofreader loads two files (which could be Word/PDF/SPL/AI/TXT etc.…), excludes what’s not relevant manually or with a template (i.e.: QRD template for cartons/labels), and presses the compare button. TVT will then show where the differences between the two files are. All the proofreader has to do is accept or reject each difference, and a file with all annotations will be generated for its audit trail report: simple, fast and, most importantly, error-free.

The EMA deals with patient-critical information

One department of the EMA uses TVT to compare the content of leaflets from Parallel Importers to the one already in the destination market. A single mistake means a patient could be put at risk and it also means they are not respecting the original Marketing Authorisation. For more details, the SOP from the EMA (and the updated SOP) gives an in-depth explanation of how they use TVT.

The EMA deals with 25 different languages

Although internal resources may be limited, the text in each language must be equally 100% error-free.

Why did the EMA initially start using TVT?

The first reason is risk avoidance: the EMA cannot afford to make a mistake, as this could ultimately impact patients. The second reason is economical. Employees at the EMA are highly qualified (in ROI terms: expensive!) so if an employee can only revise 2 leaflets per hour, the cost is very high. By implementing TVT, many more leaflets can be reviewed per hour, which significantly decreases costs. Additionally, as manual text comparison is very tiring, the implementation of TVT helped decrease employee turnover.

How much money does the EMA save by using TVT?

There is no official number; however, the EMA is actively encouraging Parallel Importers to use TVT by providing a 290€ discount for each annual update notification provided with a TVT report.

Is the EMA the only regulatory affairs body using TVT?

The ANSM, MHRA and BfArM also use TVT. Furthermore, over 1000 companies big and small across the world use it as well for ensuring consistency and accuracy in their content.

Do you need help proofreading your regulatory submissions? Try TVT

Do you want to find out more about how your proofreading life can be easier? Get in touch and we’ll tell you all about it.

Share this article

Marc Chaillou profile picture

Marc Chaillou

Head of Sales Europe and Global Strategic Projects, Schlafender Hase

Marc Chaillou is Head of Sales Europe and Global Strategic Projects at Schlafender Hase.

Learn More

Subscribe to our blog

This may come as a surprise to regulatory affairs professionals of the pharmaceutical industry, but the European Medicines Agency (EMA) has been using TVT, the Text Verification Tool® since 2004!

Why is this relevant for Regulatory Professionals and Labelling and Graphic Designers working in Pharma?
The EMA spends a lot of time comparing texts

And in simple words, that’s what TVT does. The proofreader loads two files (which could be Word/PDF/SPL/AI/TXT etc.…), excludes what’s not relevant manually or with a template (i.e.: QRD template for cartons/labels), and presses the compare button. TVT will then show where the differences between the two files are. All the proofreader has to do is accept or reject each difference, and a file with all annotations will be generated for its audit trail report: simple, fast and, most importantly, error-free.

The EMA deals with patient-critical information

One department of the EMA uses TVT to compare the content of leaflets from Parallel Importers to the one already in the destination market. A single mistake means a patient could be put at risk and it also means they are not respecting the original Marketing Authorisation. For more details, the SOP from the EMA (and the updated SOP) gives an in-depth explanation of how they use TVT.

The EMA deals with 25 different languages

Although internal resources may be limited, the text in each language must be equally 100% error-free.

Why did the EMA initially start using TVT?

The first reason is risk avoidance: the EMA cannot afford to make a mistake, as this could ultimately impact patients. The second reason is economical. Employees at the EMA are highly qualified (in ROI terms: expensive!) so if an employee can only revise 2 leaflets per hour, the cost is very high. By implementing TVT, many more leaflets can be reviewed per hour, which significantly decreases costs. Additionally, as manual text comparison is very tiring, the implementation of TVT helped decrease employee turnover.

How much money does the EMA save by using TVT?

There is no official number; however, the EMA is actively encouraging Parallel Importers to use TVT by providing a 290€ discount for each annual update notification provided with a TVT report.

Is the EMA the only regulatory affairs body using TVT?

The ANSM, MHRA and BfArM also use TVT. Furthermore, over 1000 companies big and small across the world use it as well for ensuring consistency and accuracy in their content.

Do you need help proofreading your regulatory submissions? Try TVT

Do you want to find out more about how your proofreading life can be easier? Get in touch and we’ll tell you all about it.

Subscribe to our blog

Related Blogs

Why Automated Proofreading Matters in Biotech Scale-Ups

July 4, 2025

Schlafender Hase Team

Why Automated Proofreading Matters in Biotech Scale-Ups

In a fast-scaling biotech environment, you’re managing regulatory documents, clinical content, labeling, instructions for use, artwork, and important safety information. These aren’t just words on a page, they're the backbone of your product’s journey to patients, regulators, and partners. And every version must be accurate, consistent, and audit ready.

Why Automated Proofreading Matters in Biotech Scale-Ups
2 minutes read

Why Automated Proofreading Matters in Biotech Scale-Ups

In a fast-scaling biotech environment, you’re managing regulatory documents, clinical content, labeling, instructions for use, artwork, and important safety information. These aren’t just words on a page, they're the backbone of your product’s journey to patients, regulators, and partners. And every version must be accurate, consistent, and audit ready.

Frank Hessler - CEO of Schlafender Hase

June 30, 2025

Schlafender Hase Team

Schlafender Hase Announces Change in Executive Leadership

Founder & Chief Executive Officer Frank Hessler to join advisory board; André Cerbe to continue as sole Chief Executive Officer, supported by a strong Leadership team including Chief Technology Officer Karthikeyan Pandiyan.

Frank Hessler - CEO of Schlafender Hase
2 minutes read

Schlafender Hase Announces Change in Executive Leadership

Founder & Chief Executive Officer Frank Hessler to join advisory board; André Cerbe to continue as sole Chief Executive Officer, supported by a strong Leadership team including Chief Technology Officer Karthikeyan Pandiyan.

FDA's New Front-of-Package Nutrition Labeling

June 26, 2025

Schlafender Hase Team

FDA’s New Front-of-Package Nutrition Labeling

The FDA's proposed front-of-package nutrition labeling represents one of the most significant food labeling changes in decades. This article introduces the proposed rule, countries that have already implemented it, and explores the economic and health benefits.

FDA's New Front-of-Package Nutrition Labeling
2 minutes read

FDA’s New Front-of-Package Nutrition Labeling

The FDA's proposed front-of-package nutrition labeling represents one of the most significant food labeling changes in decades. This article introduces the proposed rule, countries that have already implemented it, and explores the economic and health benefits.